Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2008

View Archived Issues

INNO-406 well tolerated in patients with advanced leukemia

Clinuvel to commence phase II CUV-1647 trials in solar urticaria

Symphogen collaborates with Genentech for antibody therapeutics

Novel agents for skin wrinkling reported by Lipotec

Apixaban begins new phase III trial in VTE

Patient enrollment begins in Reolysin phase I/II ovarian cancer trial

Avant announces research collaborations with 3M

Biovest reports blinded data from pivotal BiovaxID trial

Compugen discovers novel drug targets for cancer antibody therapeutics

Targacept and AstraZeneca evaluate AZD-3480 in phase II adult ADHD trial

Antiosteoporotic potential of denosumab evaluated in phase III studies

Phase II results with AstraZeneca's endothelin receptor antagonist ZD-4054 presented

Giripladib reduces joint destruction in mouse models of rheumatoid arthritis

Cytotoxic T-cell responses achieved with IMP-321 treatment in metastatic breast cancer patients

Pain and King submit NDA for Remoxy for moderate to severe pain

ApoCell to detect innovative biomarkers in phase II RTA-402 trial

Maxygen receives U.K. approval to initiate phase I trial of Maxy-VII for hemophilia

Morria receives South African regulatory approval to initiate phase II study of MRX-4 in AR

Duska licenses portfolio of heart failure drugs from Duke and Johns Hopkins universities

Generex initiates dosing in phase III clinical trial of oral insulin spray Generex Oral-lyn

Oncothyreon doses first patient in phase Ib PX-12 advanced metastatic cancer trial

Novo Nordisk discontinues phase III NovoSeven trial in trauma patients

Opexa reports positive 2-year data from phase I/II Tovaxin studies

BioWa licenses Potelligent technology to Novartis for antibody research

Lytix plans to initiate clinical trials for anticancer molecule Oncopore

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...